Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 20 November 2024Expected publication date: TBC